Jaime S. Vico-Rodriguez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).

Journal: Cephalalgia : an international journal of headache

Published: July 06, 2026

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Journal: Cephalalgia : an international journal of headache

Published: June 19, 2026

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Journal: Neurology

Published: May 27, 2026

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).

Journal: Cephalalgia : an international journal of headache

Published: April 01, 2026

ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.

ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.

Journal: Brain and behavior

Published: February 13, 2026

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Journal: Neurology

Published: January 28, 2026

Higher dietary polyphenol intake is associated with reduced pain sensitivity and migraine-related disability: A cross-sectional analysis.

Higher dietary polyphenol intake is associated with reduced pain sensitivity and migraine-related disability: A cross-sectional analysis.

Journal: PloS one

Published: December 12, 2025

Prospective cohort study of the impact of preventive migraine treatment on vestibular function and symptoms: The SPIRAL study.

Prospective cohort study of the impact of preventive migraine treatment on vestibular function and symptoms: The SPIRAL study.

Journal: Clinical neurology and neurosurgery

Published: September 27, 2025

SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials.

SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials.

Journal: Frontiers in neurology

Published: September 12, 2025

Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study.

Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study.

Journal: Headache

Published: September 06, 2025

Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study.

Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study.

Journal: Cephalalgia : an international journal of headache

Published: June 12, 2025

Association Between Interictal Sensory Hypersensitivities and Vestibular Symptoms in Migraine: A Cross-Sectional Study.

Association Between Interictal Sensory Hypersensitivities and Vestibular Symptoms in Migraine: A Cross-Sectional Study.

Journal: Brain and behavior

Published: June 02, 2025

Showing 1-12 of 36

Last Updated: 09/26/2026